This database contains 472 studies, archived under the term: "Pharmaceutical Interventions"
Click here to filter this large number of results.
Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia
Liu, Xuan,
Zhang, Junjian,
Sun, Dong,
Fan, Yuanteng,
Zhou, Hongbin,
Fu, Binfang
Background: Selective serotonin reuptake inhibitors improve cognition in patients with stroke and increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. However, the effects of selective serotonin reuptake inhibitors on cognition and serum BDNF levels in patients with vascular dementia are largely unknown. We performed an open-label study to investigate the effects […]
Effects of scalp acupuncture combined with auricular point sticking on cognitive behavior ability in patients with vascular dementia
Li, Si-Kang,
Ding, Ding-Ming,
Zhang, Zheng-Long,
Ma, Lan,
Huang, Hai-Yan,
Wu, Xiao-Hong
Objective: To compare the therapeutic differences among scalp acupuncture combined with auricular point sticking, body acupuncture and western medication for treatment of vascular dementia (VD).; Methods: Ninety cases were randomly divided into a combined therapy group (31 cases), a body acupuncture group (29 cases) and a western medication group (30 cases). The combined therapy group […]
Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand
Kulkantrakorn, Kongkiat,
Tanyakitpisal, Panas,
Towanabut, Somchai,
Dejthevaporn, Charungthai,
Rangseekajee, Poonsri,
Pongpakdee, Sunsanee,
Laptikultham, Somsak,
Rodprasert, Kritsada,
Setthawatcharawanich, Suwanna,
Thinkhamrop, Bandit
Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, […]
An open-label, nonplacebo-controlled study on Cistanche tubulosa glycoside capsules (Memoregain(®)) for treating moderate Alzheimer’s Disease
Guo, Qihao,
Zhou, Yan,
Wang, Chao-Jih,
Huang, Young-Ming,
Lee, Yi-Ta,
Su, Muh-Hwan,
Lu, Jiahong
Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed […]
Treadmill training as an augmentation treatment for Alzheimer’s disease: a pilot randomized controlled study
Arcoverde, Cynthia,
Deslandes, Andrea,
Moraes, Helena,
Almeida, Cloyra,
Araujo, Narahyana Bom de,
Vasques, Paulo Eduardo,
Silveira, Heitor,
Laks, Jerson
Objective: To assess the effect of aerobic exercise on the cognition and functional capacity in Alzheimer’s disease (AD) patients.; Method: Elderly (n=20) with mild dementia (NINCDS-ADRDA/CDR1) were randomly assigned to an exercise group (EG) on a treadmill (30 minutes, twice a week and moderate intensity of 60% VO₂max) and control group (GC) 10 patients. The […]
The effect of donepezil in comparison with conventional treatment on cognitive functioning and the performance of the patient in a prospective cohort of patients with Alzheimer’s disease treated in routine clinical practice in Spain
López-Pousa, S.,
Bermejo-Pareja, F.,
Frank, A.,
Hernández, F.,
León, T.,
Rejas-Gutiérrez, J.
Aims: Our aim was to perform a secondary analysis of a 12-month-long, non-blind, multi-centre prospective cost-of-illness study. The analysis assessed the effect of donepezil on cognitive functioning and the performance of patients with possible or probable Alzheimer’s disease, compared to that of other drugs for dementia.; Patients and Methods: A sample of 700 patients took […]